Insulin Prophylaxis Down-regulates Islet Antigen Expression and Islet Autoimmunity in the Low-dose Stz Mouse Model of Diabetes

References

• Castano L., Eisenbarth G. S. Type i diabetes: a chronic autoimmune disease of the human, mouserat. Ann. Rev. Immunol. 1990; 8: 647–679
   PubMed Web of Science ®Google Scholar
• Riley W. J., MacLaren N. K., Krischer J., Spillar R. P., Silverstein J. H., Schatz D. A., Shwartz S., Malone J., Shah S., Vadheim C., Rotter J. I. A prospective study of the development of diabetes in relatives of patients with insulin-dependent diabetes. N. Engl. J. Med. 1990; 323: 1167–1172
   PubMed Web of Science ®Google Scholar
• Vardi P., Crisa' L., Jackson R. A, Herskowitz R. D, Wolfsdorf J. I, Einhorm D., Linarelli D., Dolinar R., Wentworth S., Brink S. J, Starkman H., Soeldner J. S., Eisenbarth G. S. Predictive value of intravenous glucose tolerance test insulin secretion less or greater than the first percentile in islet cell antibody positive relatives of type 1 (insulin-dependent) diabetic patients. Diabetologia 1991; 34: 39–102
   Web of Science ®Google Scholar
• Palmer J. P., Asplin C. M, Clemons P., Lyen K., Tatpati O., Raghu P. K., Paquette T. L. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983; 222: 1337–1339
   PubMed Web of Science ®Google Scholar
• Harrison L. C., Honeyman M. C, DeAizpura H. J, Schmidli R. S, Colman P. G, Tait B. D., Cram D. S. Inverse relation between humoralcellular immunity to glutamic acid decarboxylase in subjects at risk of insulindependent diabetes. Lancet 1993; 341: 1365–1369
   PubMed Web of Science ®Google Scholar
• Dotta F., Gianani R., Previti M., Lenti L., Dionisi S., D'Erme M., Eisenbarth G. S., Di Mario U. Autoimmunity to the GM2–1 islet ganglioside beforeat the onset of the type 1 diabetes. Diabetes 1996; 45: 1193–1196
   PubMed Web of Science ®Google Scholar
• Bonifacio E., Bingley P. J, Shattock M., Dean B. M, Dunger D., Gale E. A.M., , Bottazzo G. F, et al. Qnantification of islet-cell antibodiesprediction of insulindependent diabetes. Lancet 1990; 335: 147–149
   PubMed Web of Science ®Google Scholar
• Rabin D. U., Pleasic S. M, Shapiro J. A, Yoo-Waren H., Oles I., Hicks J. M, Goldstein D. E., Rea P. M.M. Islet cell antigen 512 is a diabetes-specific islet autoantigen related to protein tyrosine phosphatases. J. Immunol. 1994; 152: 3183–3188
   PubMed Web of Science ®Google Scholar
• Castano L., Russo E., Zhou L., Lipes M. A., , Eisenbarth G. S, et al. Identificationcloning of a granule autoantigen (carboxypeptidase H) associated with type 1 diabetes. J. Clin. Endocrinol. Metab. 1991; 73: 1197–1201
   PubMed Web of Science ®Google Scholar
• Shah S., Malone J., Simpson N. E. A randomized trial of intensive insulin therapy in newly diagnosed insulin dependent diabetes mellitus. N. Engl. J. Med. 1989; 320: 540–544
   Web of Science ®Google Scholar
• Hramiak I., Mahon J., Finegood D., Dupre J. Effect of short course of high dose insulin treatment in insulin dependent diabetes mellitus. Clin. Invest. Med. 1991; 14: 28A
   PubMed Web of Science ®Google Scholar
• Chase H. P., Butler-Simon N., Garg S., McDuffie M., Hoops S. L., O'Brien D. A trial of nicotinamide in newly diagnosed patients with type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1990; 33: 444–446
   PubMed Web of Science ®Google Scholar
• Elliott R., Chase H. Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 1991; 34: 362–365
   PubMed Web of Science ®Google Scholar
• Godfredson G. F., Busehard K., Frandsen E. K. Reduction of diabetes incidence of BB Wistar rats by early prophylactic insulin treatment of diabetes prone animals. Diabetologia 1985; 28: 933–935
   PubMed Web of Science ®Google Scholar
• Atkinson M. A., MacLaren N. K., Lucchetta R. Insulitisdiabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990; 39: 933–937
   PubMed Web of Science ®Google Scholar
• Bowman M. A., Campbell L., Darrow B. L, Ellis T. M, Suresh A., Atkinson M. A. Immunologicalmetabolic effects of prophylactic insulin therapy in the NOD-scid/scid adoptive transfer model of IDDM. Diabetes 1996; 45: 205–208
   PubMed Web of Science ®Google Scholar
• Keller R. J., Eisenbarth G. S., Jackson R. A. Insulin prophylaxis individuals at high risk of type I diabetes. Lancet 1993; 341: 927–928
   PubMed Web of Science ®Google Scholar
• Eisenbarth G. S., Verge C. F, Allen H., Rewers M. J. The design of trials for prevention of IDDM. Diabetes 1993; 42: 941–947
   PubMed Web of Science ®Google Scholar
• Like A. A., Rossini A. A. Streptozotocin-induced pancreatic insulitis. New model of diabetes mellitus. Science (Wash. DC) 1976; 193: 415–417
   PubMed Web of Science ®Google Scholar
• Anastasi E., Tiberti C., Sensi M., Ponte E., Filippetti R., Dotta F., Vecci E., Fiori M. G., Di Mario U. Pancreatic gangliosides delay the onset of insulitishyperglycaemia in the low-dose streptozotocin mouse model. Scand. J. Immunol. 1993; 37: 308–313
   PubMed Web of Science ®Google Scholar
• Sai P., Elmansour A., Audrain M., Charbonel B., Bardet S. Quantification of human cytoplasmic islet-cell antibodies which cross-react with mouse pancreas: a follow up study in type 1 (insulin-dependent) diabetic patientsin first degree relatives. Diabetologia 1993; 36: 778–784
   PubMed Web of Science ®Google Scholar
• Svennerholm L., Fredman P. A procedure for quantitative isolation of brain gangliosides. Biochem. Biophys. Acta 1980; 617: 97–109
   PubMed Web of Science ®Google Scholar
• Williams M. A., McCluer R. H. The use of Sep-Pak C18 cartridges during the isolation of gangliosides. J. Neurochem. 1980; 35: 266–269
   PubMed Web of Science ®Google Scholar
• Svennerholm L. Chromatographic separation of human brain gangliosides. J. Neurochem. 1963; 10: 613–623
   PubMed Web of Science ®Google Scholar
• Schnedl W. J, Ferher S., Johnson J. H., Newgard C. B. STZ transportcytotoxicity. Diabetes 1994; 43: 1326–1333
   PubMed Web of Science ®Google Scholar
• Dotta F., Previti M., Nerman-Arbez M., Dionisi S., Cucinotta D., Lenti L., Di Mario U., Halban P. A. The GM2–1 ganglioside islet autoantigen in insulin-dependent diabetes mellitus is expressed in secretory granulesis not β-cell specific. Endorinology 1998; 189: 316–319
   Google Scholar
• Bjork E., Kampe O., Grawe J., Halberg A., Norheim I., Kalsson F. A. Modulation of beta-cell activityits influence on islet cell antibody (ICA)islet cell surface antibody (ICSA) reactivity. Autoimmunity 1993; 16: 181–188
   PubMed Web of Science ®Google Scholar
• Aaen K., Rygaard J., Jofensen K., Petersen H., Brogren C. H, Horn T., Bushard K. Dependence of antigen expression on functional state of beta-cells. Diabetes 1990; 39: 697–701
   PubMed Web of Science ®Google Scholar